Unknown

Dataset Information

Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe.


ABSTRACT:

Introduction

The broad and sustained efficacy of apremilast for psoriasis has been demonstrated in randomized and real-world observational studies. Data from Central and Eastern Europe (CEE) are lacking. Moreover, apremilast use in this region is limited by country-specific reimbursement criteria. This is the first study to report data on the real-world use of apremilast in the region.

Methods

APPRECIATE (NCT02740218) was an observational, retrospective, cross-sectional study assessing psoriasis patients 6 (± 1) months after apremilast treatment initiation. The study aimed to describe the characteristics of patients with psoriasis receiving apremilast, estimate treatment outcomes, including Psoriasis Area Severity Index (PASI), Body Surface Area (BSA), and Dermatology Life Q

SUBMITTER: Cetkovska P 

PROVIDER: S-EPMC9979124 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature